BioWorld

April 30, 2007

ArQule Partners ARQ 197 In Asia In Potential $123M Collaboration

ArQule Inc. entered a partnership on the lead program from its Cancer Survival Protein modulation program, a deal worth up to $123 million with Kyowa Hakko Kogyo Co. Ltd. (BioWorld Today) Read More

Pharmasset Prices IPO Lower Than Expected To Raise $45M

Novel Resistance Mechanism To Iressa, Tarceva Discovered

Hollis-Eden Trims Work Force To Focus On Hormone Bids

Project BioShield Moves Ahead With New Guidelines, and Boss

Alexza Bringing In $61M To Support Aerosol Drug Pipeline

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld Science

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...